The global cholic acid market consists of a limited number of manufacturers and increasing competition in the market. Europe and Asia-Pacific are hubs for major companies that have been generating a relatively significant market share which has turned these regions into developed markets for the product. These companies have expanded their distribution units in various other regions as well. Moreover, there are other small- and medium-scale players that generate revenue from local markets.
Industria Chimica Emiliana SRL (Italy), New Zealand Pharmaceuticals Limited (New Zealand), Daewoong Bio Inc. (South Korea), Dipharma Francis SRL (Italy), and Suzhou Tianlu Biopharmaceuticals Co. Ltd (China) are the major player in the global cholic acid market.
Industria Chimica Emiliana SRL (Italy) is a leading player in the cholic acid market. The company, along with Prodotti Chimici e Alimentari SpA (part of the ICE SpA Group), accounts for the major production of cholic acid across the globe. The company focuses primarily on expanding the areas they are already strong in such as active pharmaceutical ingredients (APIs) and bacteriological products. The company focus on an inorganic growth strategy to maintain its leading position in the market. Moreover, it entered into an agreement with Shilpa Medical Ltd for manufacturing drugs and pharmaceutical products. The company offers dehydrocholic acid and ursodeoxycholic acid in the global market. It has a strong presence in Latin America, North America, Europe, and Asia.
New Zealand Pharmaceuticals Limited is (New Zealand) a key player operating in the cholic acid market. The company is providing innovative products by strengthening research and development capabilities. The company offers pharmaceutical intermediates and ingredients such as cholic acid, dehydrocholic acid, and deoxycholic acid. The company focuses on an organic growth strategy to increase its market share in the global market.
Daewoong Bio Inc. (South Korea) is one of the top producers of APIs in Asia and one of the major exporters of APIs in regions including North America, Europe, and Japan. The company is focusing on expanding its presence in western pharmaceutical markets. The company offers ursodeoxycholic acid in the global cholic acid market.
Dipharma Francis SRL (Italy) develops and offers a wide range of APIs in the market. The company has a strong research and development base that helps it to launch innovative products in the market. It has a strong presence in European countries.
Suzhou Tianlu Biopharmaceuticals Co. Ltd (China) is a well-known Asian company offering APIs in the global market. With an annual production capacity of over 230 tons, the company produces a wide range of API products. It offers a wide range of products with respect to cholic acid in the global market. Moreover, to meet the demand from its customers, the company has invested and established a pharmaceutical intermediate project with an annual production capacity of over 530 tons of cholic products in Dezhou, Shandong province. With this expansion, the company is expected to enhance its production capacity and also its annual revenue for cholic acid products.
Threat of New Entrants
The threat of new entrants is medium in the global cholic acid market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global cholic acid market has a medium threat of new entrants, threatening the existing players.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global cholic acid market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.
In the global cholic acid industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the cholic acid market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers. Threat of Substitutes
The threat of substitutes in the global cholic acid market is medium to low. The substitute to the cholic acid can only be in the form of large molecules. Buyer propensity to substitute is low due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.
Also, the high differential advantage of the cholic acid market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong.
Intensity of Rivalry
The degree of competition in the global cholic acid market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.
